Herrera, chief executive officer and co-founder of Yuvo Health, a technology-enabled administrative and managed-care solution for federally qualified health centers based in New York City, is one of 10 winners in this year's Emerging Industry Leaders series.
Gayles, chief health officer of Hazel Health, a pediatric physical and mental telehealth provider for K-12 schools, headquartered in San Francisco, is one of 10 winners in this year's Emerging Industry Leaders series.
Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.
Dr Rosmarin explores several treatment approaches for vitiligo, including specific options for oral repigmentation treatments.
LaFeir Fry, vice president of innovation operations at the Geisinger Health System in Danville, Pennsylvania, a regional healthcare provider and health plan, is one of 10 winners in this year's Emerging Industry Leaders series.
Davidson, vice president, employee health medical operations, at Memorial Hermann Health System, in Houston is one of 10 winners in this year's Emerging Industry Leaders series.
Dr Karara provides insight into how unbranded biologics are impacting the overall treatment landscape.
Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.
Dr Rosmarin gives a brief overview of treatment pathways.